---
title: "信達生物匹妥布替尼新增適應症獲正式批准"
description: "信達生物公佈，非共價 (可逆) 布魯頓酪氨酸激酶 (BTK) 抑制劑捷帕力？(匹妥布替尼) 正式獲中國國家藥品監督管理局批准新增適應症，用於治療既往經過至少包含 BTK 抑制劑在內的一種系統治療的成人慢性淋巴細胞白血病/小淋巴細胞淋巴瘤患者。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/277349493.md"
published_at: "2026-03-01T10:15:25.000Z"
---

# 信達生物匹妥布替尼新增適應症獲正式批准

> 信達生物公佈，非共價 (可逆) 布魯頓酪氨酸激酶 (BTK) 抑制劑捷帕力？(匹妥布替尼) 正式獲中國國家藥品監督管理局批准新增適應症，用於治療既往經過至少包含 BTK 抑制劑在內的一種系統治療的成人慢性淋巴細胞白血病/小淋巴細胞淋巴瘤患者。

信達生物 (01801.HK) 公佈，非共價 (可逆) 布魯頓酪氨酸激酶 (BTK) 抑制劑捷帕力？(匹妥布替尼) 正式獲中國國家藥品監督管理局批准新增適應症，用於治療既往經過至少包含 BTK 抑制劑在內的一種系統治療的成人慢性淋巴細胞白血病/小淋巴細胞淋巴瘤患者。

### Related Stocks

- [01801.HK - 信達生物](https://longbridge.com/zh-HK/quote/01801.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals | Hong Kong-listed Chinese pharmaceutical companies are poised for profitability due to rising drug sales and lucrative li | [Link](https://longbridge.com/zh-HK/news/277340041.md) |
| Innovent Biologics' Q4 Revenue Surges 60% | Innovent Biologics' Q4 Revenue Surges 60% | [Link](https://longbridge.com/zh-HK/news/274820825.md) |
| A Look At InnoCare Pharma (SEHK:9969) Valuation As Dermatology Trials For Soficitinib Progress | InnoCare Pharma (SEHK:9969) has gained investor interest following the initiation of a Phase II/III trial for its TYK2 i | [Link](https://longbridge.com/zh-HK/news/276680348.md) |
| Erasca Conference: ERAS Teases 2026 Catalysts for Pan-RAS ERAS-0015 and Pan-KRAS ERAS-4001 | Erasca (NASDAQ:ERAS) executives discussed their strategy for targeting RAS-driven cancers and outlined upcoming clinical | [Link](https://longbridge.com/zh-HK/news/277264882.md) |
| FDA clears Merck's Numelvi, first second-gen JAK inhibitor for canine pruritus | FDA clears Merck's Numelvi, first second-gen JAK inhibitor for canine pruritus | [Link](https://longbridge.com/zh-HK/news/276988374.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。